Rexxolide contains 100 mg/ml of tulathromycin, which is widely used to treat BRD and SRD. It also has a single dose and low injection volume of 1 ml/40 kg BW, to make it more convenient.
Dechra says Rexxolide has an immune-modulating and anti-inflammatory action and offers equal viscosity and syringability as other products on the market1. It can be used for treatment and metaphylaxis of BRD and SRD and offers early-stage treatment for infectious pododermatitis.
Dechra’s Equine and Food Producing Animal Brand Manager, Emma Jennings said: “Launching Rexxolide into the market provides an alternative option to existing BRD, SRD and foot rot treatments for farm vets across the UK and Ireland.
"We support an integrated approach to the control of BRD, with good husbandry, early detection and correct therapy being vital tools in managing the multi-factorial condition."
Rexxolide is available in 50ml and 100ml vials. For more information visit www.dechra.co.uk.
Whilst you're here, take a moment to see our latest job opportunities for vets.
VetSurgeon Jobs is the place to advertise and find permanent and locum jobs for veterinary surgeons in England | Scotland | Wales | Ireland and Worldwide. Follow VS Jobs on Facebook | Linkedin | Twitter
Learn more about advertising on VetSurgeon.org
Veterinary Forums | Veterinary News | Veterinary Galleries
Veterinary Anaesthesia | Veterinary Cardiology | Veterinary Dentistry | Veterinary Dermatology | Diagnostic Imaging | Veterinary ECC | Equine Medicine & Surgery | Farm Animal Medicine & Surgery | Veterinary Medicine | Veterinary Neurology Veterinary Oncology | Veterinary Ophthalmology | Veterinary Orthopaedics | Pathology/Cytology | Veterinary Surgery